An undisclosed amount of seed funding has been provided by two UK investors for a start-up gene therapy company that is working on a concept for preventing nerve damage in glaucoma, the leading cause of irreversible blindness worldwide.
The Swedish specialty pharmaceutical company Pharmalink AB has raised SEK 100 million (€10.5 million) to prepare for a Phase 3 development programme of its candidate product for primary IgA nephropathy, an inflammatory disease of the kidney.
The Wales Life Science Fund has led a €12 million Series B funding round for drug developer Apitope in order to enable to company to progress its pipeline of peptide-based therapeutics directed at autoimmune and allergic diseases.
Austria-based Nabriva Therapeutics AG has raised $92.25 million gross in an initial public offering (IPO) of its shares on the Nasdaq market to finance development of its portfolio of anti-infective medicines. Leerink Partners LLC and RBC Capital Markets LLC jointly managed the offering.
Replimune Ltd, a UK start-up, has raised $30 million in Series A finance to develop therapeutics based on the use of oncolytic viruses, or viruses that infect and destroy cancer cells. The funding round is being led by Atlas Venture with participation from Forbion Capital Partners and Omega Funds.
Allergy Therapeutics Plc reported strong growth in European sales for the year to 30 June, giving it a platform for the future launch of its candidate short-course vaccine against grass allergy, Pollinex Quattro Grass.
Amgen Inc has moved to strengthen its cardiovascular portfolio with the agreed purchase of Dezima Pharma BV of the Netherlands which has a new drug for dyslipidemia in a Phase 2b clinical trial. Dezima is backed by Forbion Capital Partners and other venture funds.
Desktop Genetics Ltd, which brings CRISPR genome editing technology to a computer with access to the cloud, has raised £1.37 million in equity financing from a group of biotech executives, business angels and venture capitalists, including the chief executive of Syncona Partners LLP.
An experimental vaccine against the Ebola virus has received further support from the US government enabling the developers to improve their manufacturing and storage capabilities. The vaccine is being developed by Janssen Pharmaceuticals and Bavarian Nordic A/S.
Generic drug producer Mylan NV has made formal offer to buy all the outstanding shares of Perrigo Company Plc on terms that were not quite as favourable as its initial offer last April. Based in Ireland, Perrigo manufactures over-the-counter and generic drugs.